-- CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:
We keep our target at $255, 15.8x our 2026 EPS view. This is above ABBV's 10-year historical forward P/E average of 12.1x, justified by its improving long-term growth prospects. We raise our 2026 EPS view to $14.17 from $14.02 to reflect the Q1 beat and raised expectations for the rest of the year. We keep our 2027 EPS view at $16.13. ABBV reported a strong start to 2026, with Q1 results surpassing expectations. Revenues reached $15B, a 12.4% increase, beating expectations due to the continued momentum in the Immunology and Neuroscience franchises. Adjusted EPS came in at $2.65, above the guidance midpoint despite an unfavorable impact from acquired IPR&D. We think the early data from the Amylin Analog (ABBV-295) showed promising weight loss results with good tolerability. With Phase 2 studies expected to begin in Q3 2026, we think updates should be closely followed as ABBV-295 could well position AbbVie in the highly lucrative obesity market with a potentially differentiated, non-incretin-based mechanism.